CYTK (Cytokinetics) Cyclically Adjusted PB Ratio: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CYTK Cytokinetics Inc CYTK
51 GF Score
Price $77.13
GF Value $253.44
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cytokinetics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cytokinetics  (NAS:CYTK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cytokinetics Cyclically Adjusted PB Ratio Related Terms


Cytokinetics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Cytokinetics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics Cyclically Adjusted PB Ratio Chart

Cytokinetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.38 27.44 74.02 61.97 434.90

Cytokinetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.83 65.71 161.47 434.90 0.00

CYTK vs SMMT, TECH, BMRN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Cytokinetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Cyclically Adjusted PB Ratio falls into.


CYTK
51GF Score
Cytokinetics Inc CYTK
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytokinetics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cytokinetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Cytokinetics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-6.653/330.2130*330.2130
=-6.653

Current CPI (Mar. 2026) = 330.2130.

Cytokinetics Quarterly Data

Book Value per Share CPI Adj_Book
201606 1.228 241.018 1.682
201609 2.055 241.428 2.811
201612 2.321 241.432 3.174
201703 2.197 243.801 2.976
201706 3.274 244.955 4.414
201709 2.730 246.819 3.652
201712 2.036 246.524 2.727
201803 1.844 249.554 2.440
201806 1.376 251.989 1.803
201809 0.953 252.439 1.247
201812 0.474 251.233 0.623
201903 0.061 254.202 0.079
201906 -0.084 256.143 -0.108
201909 -0.336 256.759 -0.432
201912 -0.185 256.974 -0.238
202003 -0.769 258.115 -0.984
202006 -1.303 257.797 -1.669
202009 2.119 260.280 2.688
202012 1.597 260.474 2.025
202103 0.948 264.877 1.182
202106 0.229 271.696 0.278
202109 2.971 274.310 3.576
202112 2.876 278.802 3.406
202203 1.359 287.504 1.561
202206 1.297 296.311 1.445
202209 -0.169 296.808 -0.188
202212 -1.138 296.797 -1.266
202303 -2.395 301.836 -2.620
202306 -3.472 305.109 -3.758
202309 -4.559 307.789 -4.891
202312 -3.801 306.746 -4.092
202403 -3.781 312.332 -3.997
202406 0.924 314.175 0.971
202409 -0.118 315.301 -0.124
202412 -1.145 315.605 -1.198
202503 -2.235 319.799 -2.308
202506 -3.083 322.561 -3.156
202509 -4.267 324.800 -4.338
202512 -5.365 324.054 -5.467
202603 -6.653 330.213 -6.653

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cytokinetics (CYTK) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of $77.13 is trading 69.6% below its estimated GF Value™ of $253.44. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for CYTK:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $253.44 vs. price of $77.13 (69.6% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the CYTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cytokinetics Business Description

Other Exchanges 1CYTK:ItalyKK3A:Germany
Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
51GF Score

Get the complete analysis for CYTK

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$77.13
Price
$253.44
GF Value